Somatostatin Receptor Theranostics for Refractory Meningiomas.
meningioma
peptide receptor radionuclide therapy
somatostatin receptor
treatment-refractory meningioma
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
04 08 2022
04 08 2022
Historique:
received:
23
06
2022
revised:
31
07
2022
accepted:
01
08
2022
entrez:
25
8
2022
pubmed:
26
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
Somatostatin receptor (SSTR)-targeted peptide receptor radionuclide therapy (PRRT) represents a promising approach for treatment-refractory meningiomas progressing after surgery and radiotherapy. The aim of this study was to provide outcomes of patients harboring refractory meningiomas treated by 177Lu-DOTATATE and an overall analysis of progression-free survival at 6 months (PFS-6) of the same relevant studies in the literature. Eight patients with recurrent and progressive WHO grade II meningiomas were treated after multimodal pretreatment with 177Lu-DOTATATE between 2019 and 2022. Primary and secondarily endpoints were progression-free survival at 6-months (PFS-6) and toxicity, respectively. PFS-6 analysis of our case series was compared with other similar relevant studies that included 86 patients treated with either 177Lu-DOTATATE or 90Y-DOTATOC. Our retrospective study showed a PFS-6 of 85.7% for WHO grade II progressive refractory meningiomas. Treatment was clinically and biologically well tolerated. The overall analysis of the previous relevant studies showed a PFS-6 of 89.7% for WHO grade I meningiomas (
Identifiants
pubmed: 36005176
pii: curroncol29080438
doi: 10.3390/curroncol29080438
pmc: PMC9406720
doi:
Substances chimiques
Receptors, Somatostatin
0
Yttrium Radioisotopes
0
copper dotatate CU-64
0
Yttrium-90
1K8M7UR6O1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5550-5565Références
Lancet Oncol. 2016 Sep;17(9):e383-91
pubmed: 27599143
Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):316-317
pubmed: 32556482
Front Neurol. 2020 Aug 28;11:945
pubmed: 32982948
Sci Rep. 2020 Jun 23;10(1):10196
pubmed: 32576907
World Neurosurg. 2019 May;125:e248-e256
pubmed: 30684705
Eur J Nucl Med Mol Imaging. 2009 Sep;36(9):1407-16
pubmed: 19319527
Neuro Oncol. 2021 Jul 1;23(7):1139-1147
pubmed: 33556177
Curr Opin Neurol. 2021 Dec 1;34(6):857-867
pubmed: 34629433
Clin Transl Radiat Oncol. 2020 Mar 05;22:29-32
pubmed: 32195377
J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39
pubmed: 13406590
Cancer Biother Radiopharm. 2011 Dec;26(6):759-65
pubmed: 22060188
Nucl Med Biol. 2006 Oct;33(7):841-6
pubmed: 17045163
Eur J Nucl Med Mol Imaging. 2011 Feb;38(2):302-11
pubmed: 21052661
Neuro Oncol. 2014 Jun;16(6):829-40
pubmed: 24500419
Nuklearmedizin. 2020 Sep;59(5):348-355
pubmed: 32691404
Neuro Oncol. 2017 Nov 29;19(12):1576-1587
pubmed: 28605532
J Nucl Med. 1995 Oct;36(10):1902-9
pubmed: 7562062
Eur J Nucl Med Mol Imaging. 2021 Mar;48(3):913-923
pubmed: 32876706
J Nucl Med. 2021 Apr;62(4):507-513
pubmed: 32859705
J Nucl Med. 2015 Mar;56(3):347-53
pubmed: 25635133
J Neurosurg. 2017 Sep;127(3):660-669
pubmed: 27982767
J Nucl Med. 2015 Feb;56(2):171-6
pubmed: 25593116
Neuro Oncol. 2016 Nov;18(11):1538-1547
pubmed: 27106404
Cancer Biother Radiopharm. 2014 Jun;29(5):193-9
pubmed: 24811687
J Nucl Med. 2006 Oct;47(10):1599-606
pubmed: 17015894
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Neuro Oncol. 2019 Jan 1;21(1):26-36
pubmed: 30137421
Radiat Oncol. 2012 Jun 21;7:99
pubmed: 22720902
World J Nucl Med. 2019 Apr-Jun;18(2):160-170
pubmed: 31040748
J Nucl Med. 2015 Nov;56(11):1748-51
pubmed: 26294303
Int J Med Sci. 2022 Jun 21;19(7):1110-1117
pubmed: 35919813
Open Med (Wars). 2016 Jun 9;11(1):168-173
pubmed: 28352788